Liraglutide: Molecular Structure

Molecular Structure and Properties#

Liraglutide is a 31-amino-acid synthetic peptide analog of human glucagon-like peptide-1 (GLP-1), developed by Novo Nordisk. It has a molecular weight of approximately 3,751.2 Da, with the molecular formula C172H265N43O51 and CAS number 204656-20-2. Liraglutide was the first acylated GLP-1 analog to achieve once-daily dosing through fatty acid-mediated albumin binding, establishing the design principle later refined in semaglutide.

Amino Acid Sequence#

The primary structure of liraglutide is based on the native human GLP-1(7-37) sequence with 97% homology. Two modifications distinguish it from the native peptide:

His-Ala-EGTFTSDVSSYLEGQAAKEFIAWLVRGRG

with a C16 fatty acid (palmitic acid) moiety conjugated at the lysine residue at position 26 via a glutamic acid spacer.

Key residues and their functional significance:

• Position 1 (Histidine): Retained from native GLP-1; essential for GLP-1 receptor binding and activation
• Position 2 (Alanine): Retained as native alanine, unlike semaglutide which substitutes Aib at this position. This means liraglutide retains susceptibility to DPP-4 cleavage, though the albumin binding substantially reduces the rate of enzymatic degradation
• Position 26 (Lysine): Serves as the conjugation site for the C16 fatty acid (palmitic acid), attached through a glutamic acid spacer. This fatty acid modification is the primary mechanism for half-life extension
• Position 34 (Arginine): Replaces native lysine at position 34. This substitution prevents unwanted fatty acid conjugation at this site, ensuring the C16 chain attaches exclusively at Lys26

Lipid Modification and Albumin Binding#

The C16 fatty acid (palmitic acid) conjugated at Lys26 is the defining pharmacokinetic feature of liraglutide. This modification serves several purposes:

1. Albumin binding: The palmitic acid moiety binds non-covalently to serum albumin (>98% bound in plasma), creating a circulating depot that protects the peptide from renal filtration and proteolytic degradation. This extends the half-life from approximately 2 minutes (native GLP-1) to approximately 13 hours, enabling once-daily dosing.

2. Linker design: The connection between the peptide backbone at Lys26 and the palmitic acid uses a single glutamic acid spacer. This is a simpler linker design compared to the gamma-glutamic acid and mini-PEG linker used in semaglutide.

3. Self-association: At pharmaceutical concentrations, liraglutide forms heptameric complexes in solution, which further slows absorption from the subcutaneous injection site and contributes to the sustained pharmacokinetic profile.

Comparison with Semaglutide's Lipid Modification#

The evolution from liraglutide's C16 fatty acid to semaglutide's C18 fatty diacid illustrates progressive pharmacokinetic optimization:

• Chain length: Liraglutide uses C16 (palmitic acid) versus semaglutide's C18 (octadecanedioic acid). The longer chain provides stronger albumin binding affinity.
• Linker complexity: Liraglutide uses a simple glutamic acid spacer, while semaglutide uses a gamma-glutamic acid plus mini-PEG linker. The mini-PEG improves aqueous solubility.
• Half-life outcome: Liraglutide achieves approximately 13 hours (daily dosing), while semaglutide achieves approximately 7 days (weekly dosing).
• DPP-4 resistance: Semaglutide adds an Aib substitution at position 2 for DPP-4 resistance, which liraglutide lacks.

Physicochemical Properties#

Liraglutide is formulated as a clear, colorless solution for subcutaneous injection in a phosphate buffer at pH 8.15, with disodium phosphate dihydrate, propylene glycol, phenol as preservative, and hydrochloric acid/sodium hydroxide for pH adjustment.

• Solubility: Freely soluble in aqueous buffers at physiological pH
• Stability: Stable at 2-8 degrees C for the shelf life; pens may be stored at room temperature (up to 30 degrees C) for up to 30 days after first use
• Self-association: Forms zinc-free heptamers in solution at pharmaceutical concentrations

Pharmacokinetics#

Liraglutide exhibits predictable pharmacokinetics across the approved dose range.

Absorption: After subcutaneous injection, maximum plasma concentration is reached at approximately 8-12 hours post-dose. Absolute bioavailability after subcutaneous administration is approximately 55%.

Distribution: The apparent volume of distribution is approximately 11-17 liters. The high degree of albumin binding (>98%) limits extravascular distribution.

Metabolism: Liraglutide is endogenously metabolized through general protein catabolism. It is not a substrate for a specific organ as the route of elimination, and intact liraglutide is not detected in urine or feces.

Elimination: The elimination half-life is approximately 13 hours, supporting once-daily dosing. Clearance is approximately 1.2 L/hr. Steady-state concentrations are achieved after approximately 3-5 days of daily dosing.

Receptor Pharmacology#

Liraglutide is a selective GLP-1 receptor agonist with no clinically meaningful activity at the GIP receptor, glucagon receptor, or other related receptors. Its receptor binding affinity is comparable to native GLP-1. Unlike semaglutide, liraglutide does not have the Aib2 substitution that provides DPP-4 resistance, but the albumin binding effectively compensates by reducing the rate of enzymatic exposure.

Structural Comparison with Related Peptides#

• vs. Native GLP-1(7-37): Liraglutide retains 97% sequence homology with only the Arg34 substitution and the C16 fatty acid conjugation. Half-life extended from approximately 2 minutes to approximately 13 hours.
• vs. Semaglutide: Both are acylated GLP-1 analogs, but semaglutide uses a C18 diacid with mini-PEG linker and Aib2 substitution, achieving a 7-day half-life (weekly dosing) versus liraglutide's 13-hour half-life (daily dosing). Semaglutide provides greater clinical efficacy.
• vs. Exenatide: Exenatide (exendin-4) is a 39-amino-acid peptide from Gila monster venom with 53% homology to human GLP-1. It has no lipid modification and a 2.4-hour half-life (twice-daily dosing for Byetta).
• vs. Tirzepatide: Tirzepatide is a 39-amino-acid dual GIP/GLP-1 agonist with a C20 fatty diacid, providing both dual receptor activation and weekly dosing.

Related Reading#

• Liraglutide overview and research guide
• Peptides similar to Liraglutide
• Liraglutide research evidence